SPECTRAL PROVIDES CORPORATE UPDATE

TORONTO, Canada – May 30, 2018 – Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock guided by a companion diagnostic, today provided the following corporate update.

Spectral is currently undergoing an interactive dialogue with the US Food and Drug Administration (the "FDA") aimed at the collection of more information regarding safety and efficacy for the PMX cartridge as a part of the FDA approval process. The goal is to add more information to data already obtained in the EUPHRATES trial. In the EUPHRATES trial, a specific group of patients showed a 40% reduction in relative risk for death at 28-days.

The Company notes that in the TIGRIS study, Toraymyxin use to Information Gather regarding its efficacy and safety for patients with endotoxemic septic shock, was designed based on input from European clinicians familiar with use of the PMX cartridge, regulatory consultants, and advice of the US FDA. The TIGRIS design proposed to FDA is a single arm study.

In addition, Spectral has recently undergone the Medical Devices Single Audit Program (MDSAP) for its manufacturing facility located in Toronto and has received acknowledgement that it has successfully passed this audit. This audit covers regulatory requirements for manufacturing for Health Canada (HC), the US FDA and the European Union (CE Mark).

Spectral continues to develop a commercialization plan for its proprietary hemodialysis pump, as the device has achieved Health Canada, European Union (CE mark) and US FDA approval.

About Spectral

Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ ("PMX"). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.

PMX has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 150,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 350,000 patients are diagnosed with severe sepsis and septic shock in North America each year. Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information please visit www.spectraldx.com.

Forward-looking statement

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities, general economic, market and business conditions, as well as other risks and uncertainties which are more fully described in Spectral's Annual Information Form dated March 28, 2018, and in other filings of Spectral with securities and regulatory authorities which are available at www.sedar.com. Spectral does not undertake any obligation to update forward-looking statements these assumptions change. Nothing in this document should be construed as either an offer to sell or a solicitation to buy or sell Spectral securities.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

For further information please contact:

Dr. Paul Walker
President and CEO
Spectral Medical Inc.
416-626-3233 ext. 2100
pwalker@spectraldx.com

Ali Mahdavi
Capital Markets & Investor Relations
416-962-3300
am@spinnakercmi.com